TriangleDISEASE & TREATMENT SETTING
Prostate Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Prostate Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Prostate Cancer. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
41 more-specific settings
Casodex: advanced Prostate Cancer →Rubraca: metastatic Prostate Cancer with BRCA mutation after prior therapy →Jevtana: metastatic Prostate Cancer →AKEEGA: metastatic Prostate Cancer with BRCA stated without a specific alteration →Docetaxel: metastatic Prostate Cancer →ELIGARD: advanced Prostate Cancer →LEUPROLIDE ACETATE DEPOT: advanced Prostate Cancer →ERLEADA: metastatic Prostate Cancer →NUBEQA: metastatic Prostate Cancer →AKEEGA: metastatic Prostate Cancer with BRCA2 stated without a specific alteration →LUTRATE DEPOT: advanced Prostate Cancer →Vabrinty: advanced Prostate Cancer →Lynparza: metastatic Prostate Cancer after prior therapy →PROVENGE: metastatic Prostate Cancer →Talzenna: metastatic Prostate Cancer →BEIZRAY: metastatic Prostate Cancer →Lynparza: metastatic Prostate Cancer with BRCA stated without a specific alteration →Lupron Depot: advanced Prostate Cancer →Bicalutamide: metastatic Carcinoma of the Prostate →Xofigo: metastatic Prostate Cancer →DOCIVYX: metastatic Prostate Cancer →Zytiga: metastatic Prostate Cancer →Orgovyx: advanced Prostate Cancer →YONSA: metastatic Prostate Cancer →PLUVICTO: metastatic Prostate Cancer →ABIRATERONE ACETATE: metastatic Prostate Cancer →PLUVICTO: metastatic Prostate Cancer after prior therapy →ZOLADEX: advanced Carcinoma of the Prostate →Rubraca: metastatic Prostate Cancer with BRCA stated without a specific alteration, BRCA mutation after prior therapy →CAMCEVI: advanced Prostate Cancer →FIRMAGON: advanced Prostate Cancer →Trelstar: advanced Prostate Cancer →TRUQAP: metastatic Prostate Cancer →Rubraca: metastatic Prostate Cancer with BRCA mutation after prior therapy →CASODEX: metastatic Carcinoma of the Prostate →Xtandi: metastatic Prostate Cancer →Stage I Prostate Cancer →Stage II Prostate Cancer →Stage III Prostate Cancer →Stage IV Prostate Cancer →recurrent Prostate Cancer →
Study evidence for this setting
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Performance Evaluation of the AMS CONTINUUM™ Device
Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Indication-specific source history
1995-10-04 · Casodex (bicalutamide) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- event id
- fda-f82c8e374a0e4f79
- event date
- 1995-10-04
- event kind
- accelerated-approval
- drug or regimen
- Casodex (bicalutamide)
- source indication text
- In combination with an LHRH analogue for advanced prostate cancer
- match phrase
- prostate cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-4fa41f35f1bc10eb803c
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
1997-12-12 · Casodex (bicalutamide) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- event id
- fda-13c8ba9be389d78d
- event date
- 1997-12-12
- event kind
- traditional-approval
- drug or regimen
- Casodex (bicalutamide)
- source indication text
- In combination with an LHRH analogue for advanced prostate cancer
- match phrase
- prostate cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-4fa41f35f1bc10eb803c
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-05-15 · Rubraca (rucaparib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- event id
- fda-8c96c2d6688490ef
- event date
- 2020-05-15
- event kind
- accelerated-approval
- drug or regimen
- Rubraca (rucaparib)
- source indication text
- Treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy
- match phrase
- prostate cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-307341947c3b214bb082
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-03-28 · lutetium Lu 177 vipivotide tetraxetan · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- event id
- notice-80d5bc957bd6f4e1
- event date
- 2025-03-28
- event kind
- approval-notification
- drug or regimen
- lutetium Lu 177 vipivotide tetraxetan
- source indication text
- FDA approved lutetium Lu 177 vipivotide tetraxetan to include adults with prostate-specific membrane antigen -positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibitor therapy and are considered appropriate to delay taxane-based chemotherapy.
- match phrase
- prostate cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-f48b23d099252406
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-06-03 · darolutamide · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- event id
- notice-d441b9d7c1e60b9c
- event date
- 2025-06-03
- event kind
- approval-notification
- drug or regimen
- darolutamide
- source indication text
- FDA approved darolutamide for metastatic castration-sensitive prostate cancer . The FDA previously approved darolutamide in combination with docetaxel for mCSPC.
- match phrase
- prostate cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-6a8e7d45487d2138
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-12-12 · niraparib and abiraterone acetate plus prednisone · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- event id
- notice-b43203aa36b47ddf
- event date
- 2025-12-12
- event kind
- approval-notification
- drug or regimen
- niraparib and abiraterone acetate plus prednisone
- source indication text
- FDA approved niraparib and abiraterone acetate with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer, as determined by an FDA-approved test.
- match phrase
- prostate cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-3afb067b5b05cacc
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-12-17 · Rubraca (rucaparib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- event id
- fda-5c38c063a347499d
- event date
- 2025-12-17
- event kind
- traditional-approval
- drug or regimen
- Rubraca (rucaparib)
- source indication text
- Treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy
- match phrase
- prostate cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-307341947c3b214bb082
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-12-17 · rucaparib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- event id
- notice-51ecf5668b51f55a
- event date
- 2025-12-17
- event kind
- approval-notification
- drug or regimen
- rucaparib
- source indication text
- FDA approved rucaparib for adults with a deleterious BRCA mutation -associated metastatic castration-resistant prostate cancer previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic . Rucaparib was granted accelerated approval in 2020 for a similar indication.
- match phrase
- prostate cancer
- match status
- candidate
- status category
- regular
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-2f7bc8b820239b15
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-06-12 · capivasertib with abiraterone and prednisone · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- event id
- notice-08024854b1a9d30a
- event date
- 2026-06-12
- event kind
- approval-notification
- drug or regimen
- capivasertib with abiraterone and prednisone
- source indication text
- FDA approved capivasertib in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is PTEN-deficient as detected by an FDA-authorized test.
- match phrase
- prostate cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-b7661f27f59bbecb
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-07-31 · lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- event id
- notice-83d3082f747b07a0
- event date
- 2026-07-31
- event kind
- approval-notification
- drug or regimen
- lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy
- source indication text
- FDA approved lutetium Lu 177 vipivotide tetraxetan in combination with androgen receptor pathway inhibitor therapy for adults with prostate-specific membrane antigen -positive metastatic androgen pathway modulation-naïve or-sensitive prostate cancer .
- match phrase
- prostate cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-036eff4becf1a0e2
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-prostate-cancer
- binding id
- ncit-C4863
- source collection
- ncit-concept
- source key
- C4863
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice